ADAR1 Capital Management »

Cytokinetics shares owned by ADAR1 Capital Management

Quarter-by-quarter ownership of Cytokinetics (CYTK) shares owned by ADAR1 Capital Management from 13F filings

Historical chart of ADAR1 Capital Management investment in Cytokinetics

Tip: Access up to 7 years of quarterly data

All positions including Cytokinetics held by ADAR1 Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Cytokinetics by ADAR1 Capital Management

Quarter filed Position value Share count Share price at filing
2024-03-31 $23M 322k 70.11
2023-12-31 $14M 169k 83.49

More positions owned by ADAR1 Capital Management

Alnylam Pharmaceuticals (ALNY)
Ea Series Trust Alpha Arch 1-3 (BOXX)
Roivant Sciences SHS (ROIV)
Spdr S&p 500 Etf Tr Tr Unit Put Option (SPY)
Protagonist Therapeutics (PTGX)
Cytokinetics Com New (CYTK)
Keros Therapeutics (KROS)
Royalty Pharma Shs Class A (RPRX)
Bridgebio Pharma (BBIO)
Merrimack Pharmaceuticals In Com New
Ascendis Pharma A/s Sponsored Adr (ASND)
Arbutus Biopharma (ABUS)
Avrobio Ord (AVRO)
Beigene Sponsored Adr (BGNE)
Invesco Qqq Tr Unit Ser 1 Put Option (QQQ)

View all positions for ADAR1 Capital Management

Top funds holding Cytokinetics

BlackRock
BlackRock
Vanguard Group
T. Rowe Price Investment Management
State Street Corporation
Bank of America Corporation
T. Rowe Price Associates
Armistice Capital
Geode Capital Management
Pentwater Capital Management
Boxer Capital
Pictet Asset Management Holding SA
Alliancebernstein
Marshall Wace
Partner Fund Management

View all funds holding Cytokinetics